DDW 2022 Conference Coverage
Playback speed
10 seconds
Efficacy and Safety of Mirikizumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From The Phase 3 LUCENT-2 Study
By
DDW 2022 Conference Coverage
FEATURING
Marla Dubinsky
By
DDW 2022 Conference Coverage
FEATURING
Marla Dubinsky
431 views
June 29, 2022
Mirikizumab was approved by the FDA on October 26, 2023
Comments 0
Login to view comments.
Click here to Login
Videos